LCM
CASI

Laurion Capital Management’s CASI Pharmaceuticals CASI Stock Holding History

Laurion Capital Management’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-5,573
Closed -$232K – 1345
2018
Q1 		$232K Buy
+5,573
New +$208K ﹤0.01% 1195

Other funds holding CASI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Laurion Capital Management's CASI Position: Q2 2018 in Review

Laurion Capital Management sold out of CASI Pharmaceuticals (CASI) in Q2 2018, closing a stake of 5,573 shares — an estimated $232K sold.

Laurion Capital Management first reported a position in CASI in Q1 2018 and held it in 1 quarter. The position peaked at $232K in Q1 2018. 57 funds tracked by Wall St. Rank hold CASI as of Q2 2018.

  • Laurion Capital Management reported no remaining CASI Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Laurion Capital Management sold 5,573 CASI Pharmaceuticals shares in Q2 2018, an estimated $232K.
  • Laurion Capital Management first reported a position in CASI Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Laurion Capital Management's CASI Pharmaceuticals position peaked at $232K in Q1 2018.
  • 57 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2018.

Based on Laurion Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.